IN2012DN02981A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02981A
IN2012DN02981A IN2981DEN2012A IN2012DN02981A IN 2012DN02981 A IN2012DN02981 A IN 2012DN02981A IN 2981DEN2012 A IN2981DEN2012 A IN 2981DEN2012A IN 2012DN02981 A IN2012DN02981 A IN 2012DN02981A
Authority
IN
India
Prior art keywords
fragment
fusion
variant
derivative
inflammation
Prior art date
Application number
Other languages
English (en)
Inventor
Martina Kalle
Gopinath Kasetty
Nils Martin Malmsten
Praveen Papareddy
Artur Schmidtchen
Bjorn Ulrik Walse
Original Assignee
Ximmune Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ximmune Ab filed Critical Ximmune Ab
Publication of IN2012DN02981A publication Critical patent/IN2012DN02981A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
IN2981DEN2012 2009-09-22 2010-09-21 IN2012DN02981A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0916578.8A GB0916578D0 (en) 2009-09-22 2009-09-22 Polypeptides and uses thereof
PCT/GB2010/001780 WO2011036444A1 (en) 2009-09-22 2010-09-21 Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity

Publications (1)

Publication Number Publication Date
IN2012DN02981A true IN2012DN02981A (ja) 2015-07-31

Family

ID=41278086

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2981DEN2012 IN2012DN02981A (ja) 2009-09-22 2010-09-21
IN3368DEN2012 IN2012DN03368A (ja) 2009-09-22 2010-09-22

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN3368DEN2012 IN2012DN03368A (ja) 2009-09-22 2010-09-22

Country Status (12)

Country Link
US (2) US9169315B2 (ja)
EP (2) EP2480244A1 (ja)
JP (2) JP2013505030A (ja)
CN (2) CN102655874B (ja)
AU (2) AU2010299630A1 (ja)
BR (2) BR112012006502A2 (ja)
CA (2) CA2774288A1 (ja)
EA (1) EA201200515A1 (ja)
GB (1) GB0916578D0 (ja)
IN (2) IN2012DN02981A (ja)
MX (1) MX2012003425A (ja)
WO (2) WO2011036444A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003787A2 (pt) * 2011-08-23 2020-10-27 Synapse B.V. inibidores termoestáveis de ativação do sistema de coagulação sanguínea por contato com superfícies estranhas
RU2476231C1 (ru) * 2011-10-11 2013-02-27 Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Способ купирования некроза краев кожи послеоперационной раны после эндопротезирования голеностопного сустава
GB2500184A (en) * 2012-03-12 2013-09-18 Ximmune Ab Polypeptide derived from helix A of heparin cofactor II
CN104292309B (zh) * 2014-09-29 2017-04-12 广西中医药大学 一种小分子多肽
JPWO2016104436A1 (ja) * 2014-12-22 2017-10-26 国立大学法人 岡山大学 サイトカインストーム抑制剤
RU2606836C2 (ru) * 2015-03-12 2017-01-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Антикоагулянтный, антитромбоцитарный и фибриндеполимеризационный комплекс на основе гепарина, способ его получения и применение
RU2610433C1 (ru) * 2016-02-17 2017-02-10 Людмила Анисимовна Ляпина Антикоагулянт
CN107875372A (zh) * 2017-12-20 2018-04-06 辽宁师范大学 重组肽rLj‑112在制备协同肝素抗凝药物中的应用
CN108338163A (zh) * 2018-03-28 2018-07-31 陈太师 一种持效型杀菌灭藻剂的制备方法
WO2019230509A1 (ja) * 2018-05-31 2019-12-05 国立大学法人 岡山大学 活性酸素の産生抑制剤及び／又は消去促進剤
US20210196787A1 (en) * 2018-06-28 2021-07-01 National University Corporation Okayama University Agent for enhancing phagocytosis ability of neutrophils
WO2020035588A1 (en) * 2018-08-16 2020-02-20 Roche Diagnostics Gmbh Circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy
CN109432513B (zh) * 2018-12-12 2021-03-23 中国医科大学 一种具有抗血栓再形成功能的生物材料及其制备方法
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
CN114364394A (zh) * 2020-05-26 2022-04-15 约翰内斯·古滕伯格美因兹大学医学院 用于治疗冠状病毒感染及相关凝血病的方法和组合物
CN117683081A (zh) * 2021-09-24 2024-03-12 江西康之康中药科技有限公司 一种降血压肽及其在降血压制品上的应用
CN114886116B (zh) * 2022-03-18 2023-11-21 广东丸美生物技术股份有限公司 一种调理育龄女性健康的组合物及其制备方法和饮料及应用
CN116836233B (zh) * 2023-08-31 2023-11-14 中国农业大学 抗炎活性多肽及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5118793A (en) * 1989-10-20 1992-06-02 Washington University Modified heparin cofactor II
US5102995A (en) * 1989-10-20 1992-04-07 Washington University Dna encoding modified heparin cofactor ii
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
WO1992018139A1 (en) 1991-04-09 1992-10-29 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5712247A (en) * 1995-02-21 1998-01-27 University Of North Carolina Use of lactoferrin to modulate and/or neutralize heparin activity
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6946439B2 (en) * 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
WO1999043810A1 (en) * 1998-02-27 1999-09-02 The University Of North Carolina At Chapel Hill Mutant heparin cofactor ii
AU1410801A (en) * 1999-11-17 2001-05-30 Compugen Ltd. Variants of alternative splicing
WO2003007689A2 (en) * 2001-07-20 2003-01-30 Eidgenoessische Technische Hochschule Zurich (Ethz) Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
GB0131112D0 (en) 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
EP1530629B1 (en) * 2002-05-31 2011-08-31 The University of Utah Research Foundation Variants of antithrombin iii
CN101804200A (zh) * 2002-11-22 2010-08-18 余芒 广谱抗病毒的治疗和预防
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005015206A2 (en) * 2003-08-08 2005-02-17 Genova Ltd. Secreted polypeptide species associated with cardiovascular disorders
CA2560103A1 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
CA2607293A1 (en) * 2005-05-06 2006-11-16 Novartis Ag Use of tfpi to treat severe bacterial infections
EP1913025A2 (en) * 2005-07-22 2008-04-23 Novartis AG Anti-microbial agents that interact with the complement system
LT1981519T (lt) * 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
EP3088522B1 (en) * 2005-12-29 2017-11-29 The Regents of the University of California Methods and compositions related to mutant kunitz domain i of tfpi-2
US8076286B2 (en) * 2006-02-10 2011-12-13 Dermagen Ab Antimicrobial peptides and use thereof
WO2008127702A2 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
RU2010102865A (ru) * 2007-07-24 2011-08-27 НексБио, Инк. (US) Технология изготовления микрочастиц

Also Published As

Publication number Publication date
EA201200515A1 (ru) 2012-10-30
IN2012DN03368A (ja) 2015-10-23
JP2013505030A (ja) 2013-02-14
CA2774296A1 (en) 2011-03-31
BR112012006501A8 (pt) 2017-07-11
WO2011036444A4 (en) 2011-06-23
CA2774288A1 (en) 2011-03-31
EP2480564A2 (en) 2012-08-01
CN102639556A (zh) 2012-08-15
CN102655874A (zh) 2012-09-05
GB0916578D0 (en) 2009-10-28
AU2010299631A1 (en) 2012-05-03
EP2480244A1 (en) 2012-08-01
BR112012006501A2 (pt) 2016-08-16
AU2010299630A2 (en) 2012-05-03
WO2011036444A1 (en) 2011-03-31
US20120177715A1 (en) 2012-07-12
WO2011036445A3 (en) 2011-09-01
AU2010299630A1 (en) 2012-04-26
BR112012006502A2 (pt) 2016-08-16
JP2013505286A (ja) 2013-02-14
WO2011036445A2 (en) 2011-03-31
US20120189673A1 (en) 2012-07-26
CN102655874B (zh) 2015-06-10
MX2012003425A (es) 2012-10-09
US9169315B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
IN2012DN02981A (ja)
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
EP2470559A4 (en) COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
MX2009002816A (es) Proteinas de fusion de albumina.
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2009012609A (es) Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
TNSN08064A1 (en) Albumin fusion proteins
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2012122042A3 (en) Peptide linkers for polypeptide compositions and methods for using same
MX2016002556A (es) Métodos y composiciones para el tratamiento de patologías del tejido de cartílago y disco.